SCHEMBL614144

SCHEMBL614144

CCCCNc1cc(-c2ccncc2)sc1C(N)=O

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.54
DBF4 Q9UBU7 1/20 0.54
IKBKB O14920 11/20 0.50
KDM6B O15054 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
ROCK2 O75116 1/20 0.44
MAP4K4 O95819 1/20 0.44
PIM1 P11309 1/20 0.44
PRKACA P17612 1/20 0.44
CDK2 P24941 1/20 0.44
GSK3B P49841 1/20 0.44
HIPK2 Q9H2X6 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
ALOX15 P16050 3/20 0.43
JAK2 O60674 1/20 0.41
LIMK1 P53667 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL613122 0.93 CDC7 (0.57) CDC7DBF4IKBKBKDM6BKDM4C
SCHEMBL613639 0.89 KDM6B (0.52) CDC7DBF4KDM6BKDM4CROCK2
SCHEMBL613690 0.87 CDC7 (0.59) CDC7DBF4IKBKBROCK2MAP4K4
SCHEMBL612320 0.87 KDM4E (0.48) KDM6BKDM4C
SCHEMBL611071 0.81 KDM6B (0.50) CDC7DBF4IKBKBKDM6BKDM4C
SCHEMBL612250 0.80 IKBKB (0.70) CDC7DBF4IKBKBCDK2JAK2
SCHEMBL613988 0.79 KDM4E (0.50) LIMK1
SCHEMBL614262 0.78 CDC7 (0.65) CDC7DBF4IKBKBKDM6BKDM4C
SCHEMBL614239 0.77 CDC7 (0.59) CDC7DBF4IKBKBCDK2JAK2
SCHEMBL613433 0.76 PTPN1 (0.48) CDC7DBF4IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403857-B1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-12-04 EP disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed
EP-2403857-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2012-01-11 EP disclosed
WO-2010101302-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS CDC7, CDK7, DTYMK CDC7 1/4885DBF4 593/4885IKBKB 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.